How hayfever works: The Full Evidence

Can genetics predict allergy severity?

What the research says

Genetics can predict allergic rhinitis susceptibility with moderate reliability, with GWAS studies identifying at least 10 key susceptibility genes (including TLR6, STAT6, IL4R, FLG, and HLA variants) collectively accounting for ~25% of disease risk. However, the evidence for predicting allergy severity specifically—as opposed to disease onset—remains underdeveloped, with most studies examining susceptibility rather than symptom severity stratification or treatment response. Emerging findings on gene-gene interactions (e.g., epistasis between FLG and IL4R) and machine learning approaches using polygenic SNP profiles show promise for more nuanced personalized prediction.

How it works

Risk variants in Th2 cytokine signaling pathways (IL-4, IL-13, IL4R) drive IgE class-switching and mast cell/eosinophil activation, while epithelial barrier genes (FLG) facilitate allergen sensitization; epistatic interactions between these pathways—such as FLG effects being amplified or masked depending on IL4R rs3024676 genotype—modulate individual immune responses and likely influence disease expression and severity.

---

Do blood IgE levels correlate with symptoms?

What the research says

Allergen-specific IgE (sIgE) levels show a modest positive association with allergic rhinitis symptom severity, with higher sIgE levels correlating with greater ARIA-classified severity across multiple studies, while total serum IgE demonstrates no reliable correlation with symptom burden. Evidence from studies ranging from 53 to 295 patients suggests sIgE thresholds (e.g., >50 kU/L) predict higher symptom loads, and sIgE levels rise significantly across mild-to-severe persistent AR categories (e.g., 6.91 to 30.7 kU/L across severity groups, p=0.0032). However, a 1986 study found no such correlation in untreated seasonal AR patients, and the overall relationship remains inconsistent across study designs and allergen types.

How it works

Elevated sIgE binds to high-affinity FcεRI receptors on mast cells and basophils in the nasal mucosa; upon allergen re-exposure, cross-linking triggers degranulation, releasing histamine, leukotrienes, and cytokines that drive Th2-mediated inflammation and eosinophil recruitment, with the degree of IgE-mediated sensitization scaling the inflammatory response. Total IgE reflects polyclonal atopic sensitization without allergen specificity, explaining its failure to predict localized nasal symptom severity.

---

Can wearable data predict inflammation?

What the research says

Wearable-derived physiological signals—particularly heart rate variability (HRV), resting heart rate, skin temperature, SpO2, and activity levels—demonstrate meaningful capacity to predict systemic inflammatory states, with changes detectable weeks before clinical flares in conditions such as IBD and RA. Machine learning models applied to these continuous data streams have achieved up to 90% sensitivity for detecting pre-symptomatic immune responses in viral respiratory contexts, and LPS-challenge studies confirm that wearable patches can track acute inflammatory biomarker dynamics in controlled settings. However, no studies directly link wearable metrics to allergic rhinitis-specific inflammation markers such as eosinophil counts, nasal cytokines, or Th2-driven immune activity.

How it works

Systemic inflammation triggers autonomic nervous system dysregulation via proinflammatory cytokines (e.g., IL-6, TNF-α), causing vagal withdrawal and sympathetic activation that manifests as reduced HRV, elevated resting HR, and disrupted circadian rhythms—all measurable by consumer wearables. These autonomic shifts precede clinical symptom onset by days to weeks, providing a physiological window for predictive modelling, though this mechanism is validated primarily for innate/systemic inflammation rather than Th2-mediated allergic cascades.

---

Does HRV correlate with allergy severity?

What the research says

HRV does correlate with allergy severity in allergic rhinitis, but the direction of this correlation is inconsistent across studies. Severe allergy states tend to show reduced SDNN and RR intervals (suggesting sympathetic predominance), while non-acute or chronic AR phases often show increased HRV indices and parasympathetic predominance compared to controls. Daily symptom burden is associated with modest next-day resting heart rate increases, though effect sizes are small.

How it works

Allergic inflammation disrupts autonomic balance via neurovisceral pathways, with inflammatory mediators (e.g., histamine, cytokines) modulating both sympathetic and vagal tone; the net effect may shift depending on disease phase, with acute inflammation driving sympathetic overactivation and chronic low-grade inflammation potentially enhancing compensatory parasympathetic activity.